Member Info for itsallamess

News items out all seem positive

Ie proactive article... new life breathed into T

Andrew scot says he hoping to get an interview with faRN

And this also, thanks Tiburn

 We know that HAD001 is not an isolated outcrop of gold, mineralisation does extend towards HAD003, which still had 21m at 3.78g/t gold and 0.44% copper

 200m west of HADOO1 is HADOO5 first drill of this campaign and 239m of mineralisation – assume this is ore bearing and has viable g/t gold – cut off point in recent times is 0.5 g/t as long as the scale is there.

 So as an absolute minimum core mineralised zone – a triangular area between drills 1, 3 and 5 is 200m x 200m by 200m = 20,000 sq m

 Depth assumed to be 800m maxi so 16 million cubic metres
 One Cubic metre of rock is equivalent to 2.32 metric tons per cubic metre
 = 16million m3 x 2.32 = 37 million tonnes
 Assuming 2g/t average = 74 million Grams (but with bonanza grades this could be a much higher average)
 Gram to troy ounce conversion at 1 g = 0.03 oz = 2.2 million oz minimum

This is knowing what we know now and assuming HAD005 has hit gold – objectively this potential amount can only get bigger as more drilling is undertaken
 Assuming the other nine drills position are in a radius of 180 degrees south and west of HAD001, extending out 200m or further? Greatland are systematic in their exploration, HAD006 location perhaps 100m SE of HAD005 and so on, completing this radius

 If this zone from HAD001 extending out at least 200m in the direction of each successful drill is prospective then we have a substantial gold bearing system worth many multiples of current market cap.

 Three weeks now to HAD005 assay resultsBPCVote

Hope you dont mind me reposting this.. excelent post!

Shareprice interview of Oct 2nd key points review again:

“Greatland attracting a lot of attention across the industry, they know who we are, know the story”

1. Ten drill campaign ongoing – GGP very enthused by seeing 239m of mineralisation “this is big news for us, we believe this is a very important development”
2. Rock in HAD005 very similar to that seen at HAD001 –chalcopyrite is copper ore bearing rock, quartz veining associated with gold deposits.
3. Black Hills 3DIP completed – awaiting results of modelling to determine extent and orientation of mineralisation to enable drill planning
4. Firetower drilling January confirmed
5. Scallywag MMI completed – results due back soon to assist in drill planning
6. Paterson region has so much activity going on, more infrastructure going in, makes development easier for all miners and investment case benefits for explorers to sell assets
7. Paterson East has 12 targets with similar geophysical signature to Havieron –- 12 targets – and they look much bigger in scale as well according to the Aeromagnetics survey map on the company website. If Havieron drilling has proven the accuracy of this survey, why not these other large targets? GH paused for effect in the interview to emphasise how big this license could be - its just off the scale. This is a superb asset to have in the company and 100% owned – expect some deal making activity for some of these as GGP cant possibly explore and drill all these targets themselves –they need a JV and finance. I wouldn’t expect Rio to hang around either whilst GGP take years evaluating these 12 target areas.

If Scallywag MMI is positive then I expect Rio to react fast in developing their Holocene license area to the south which the target area goes into. Also expect announcements soon on their potential copper discovery 100km NNW of Havieron, additional actions potential by Artemis, Newcrest and Antipa surrounding GGP licenses

Thanks click

Justbwhen toime seems short and your busy or shares get put in the bottom draw you loose track.

Manifesto
To be fair they may have to do trials again with paitients not on steriods for conclusive results

Could well of ben a trade from this morning. The MMs dont have to record trades as soon as they are made. Just a trade thats late reported

Was on the ball here and full upto date.

Would appreciate if Anyone got a quick summation of whats next news expected?

( I know it sounds lazy to ask someone else but i have in the past put the effort in to make informed posts myself:)

What GR did for his grand he earned today.. im sure it added shareholder value ! Lol

News loks good, when further reports are in it could be all systems go and we could be back to 850.... why not?

Anyone in on the drop was given a gift. I have no funds available else i would have averaged down... shame.

Lets see where we are tomorrow.
# Presention now
# maybe an interview tomorrow
# london investor thing on nov 1st
# jap results (knowing the corticosteroids effect)
# YODA
#50 healthy people being tested tests

Thats just the big T drug

Then we have the cleaver cleaver drug

Fare point chancers

Dont get me wwrong i like to bash rampers and derampers at times.

Just todays news with FARN is big, lots happening so cant be bothered today with reading loads of posts bashing

https://www.proactiveinvestors.co.uk/companies/news/207591/faron-s-follow-up-investigations-may-breathe-new-life-into-traumakine-development-207591.html

Thchancers

Ive reported you for filling the BB with your personal mission to bash other posters.

Lets talk about FARN instead

http://www.morningstar.co.uk/uk/news/AN_1540218723213166200/faron-reports-corticosteroids-interference-in-traumakine-trial.aspx
LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Monday that it has found evidence suggesting that corticosteroids used in parallel to its Traumakine treatment had a significant effect on mortality in the trial.

Faron shares were trading down 18% at 95.35 pence each.

Earlier this year, Faron had reported unsuccessful results from the testing of Traumakine in a phase III INTEREST trial for the treatment of acute respiratory distress syndrome.

In early May, Faron had reported "extremely disappointing" phase III results for Traumakine compared to a placebo.

The company decided to carry out further "post-hoc data analysis", which discovered that concomitant use of corticosteroids and Traumakine appeared to affect both the mortality and biomarker appearance in the INTEREST study patients.

The new results showed that the rate of mortality was 11% for the patients receiving Traumakine and not on corticosteroids, versus 40% for those receiving Traumakine and on corticosteroids.

Faron Chief Medical Officer Matti Karvonen said: "At this stage it appears possible that unexpectedly high corticosteroid use in the INTEREST trial may have masked the treatment benefit of Traumakine in acute respiratory distress syndrome patients."

The company is awaiting results from two further studies to decide the next steps for Traumakine's development

No spare cash else would have topped up!

Seems that way, lots of buys though.

I was thinking that there are a lot who bought in hoping for a big rise, bag really quick, but if they have to wait then they probably got bored

The big drop occured there was loads on here shoating doom and gloom, that FARN was dead in the water.

Not so, might need confirmation of what they ahcve found out before rerate. But dont be disapointed if it doesnt happen by 4.30

Still lots of news flow to come out before chrismas

So corticosteroids are give to ARDS paitents, but its questionable if its really goodmfor them

Also it turns out that cause the test subjects were on them they acually interfered with Traumakine working

Next steps
"already underway is a test of 50 healthy volunteers to determine the optimum mechanism of administration to achieve a full biomarker response with first results expected in Q4 2018"

Dr Matti Karvonen, Chief Medical Officer of Faron, said: "At this stage it appears possible that unexpectedly high corticosteroid use in the INTEREST trial may have masked the treatment benefit of Traumakine in ARDS patients. Therefore, the Company and the investigators await data from the ongoing Phase III ARDS trial with Japanese partner Maruishi, expected later this year, and further experimental data on lung tissue samples and YODA results, to determine the next steps for Traumakine's development."

https://uk.advfn.com/stock-market/london/faron-pharma-FARN/share-news/Faron-Pharmaceuticals-Oy-INTEREST-trial-update-pre/78509800

Now